Phaseline

Companies › MediLink Therapeutics (Suzhou)

MediLink Therapeutics (Suzhou): clinical trials, targets and expected readouts

7 active drug programs in 22 registered trials: 12 Phase 1, 6 Phase 3, 4 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YL202
EGFR-targeted therapy
–Phase 3Locally Advanced or Metastatic Breast Cancer; Non-Small Cell Lung Cancer; NSCLC; Non Small Cell Lung Cancer …Nov 2026
YL201
B7H3-targeting antibody-drug conjugate
B7H3Phase 3Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Advanced Esophageal Squamous Cell Carcinoma; SCLC, Extensive Stage …Jan 2027
Ivonescimab (AK112)
Bispecific antibody targeting PD-L1 and CTLA-4
PDCD1LG1, PDCD1LG2Phase 1Advanced Solid TumorsJan 2027
YL205–Phase 1Advanced Solid TumorsJul 2027
YL217–Phase 1Advanced Solid TumorJul 2028
YL242–Phase 1Advanced Solid TumorSep 2028
YL211–Phase 1Advanced Solid TumorsJun 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06107686YL202Phase 2NSCLCOncologyNov 2026
NCT05653752YL202Phase 1Non Small Cell Lung CancerOncologyDec 2026
NCT07208773YL201Phase 1Advanced Solid TumorsOncologyJan 2027
NCT07208773Ivonescimab (AK112)Phase 1Advanced Solid TumorsOncologyJan 2027
NCT07202364YL202Phase 2Non Small Cell Lung CancerOncologyJan 2027
NCT06241846YL201Phase 2Metastatic Castration-resistant Prostate Cancer (mCRPC)OncologyFeb 2027
NCT05434234YL201Phase 1Advanced Solid TumorOncologyApr 2027
NCT06439771YL202Phase 2Locally Advanced or Metastatic Breast CancerOncologyJul 2027
NCT06459973YL205Phase 1Advanced Solid TumorsOncologyJul 2027
NCT07169994YL202Phase 1Advanced Solid TumorsOncologyNov 2027
NCT06629597YL201Phase 3Nasopharyngeal CarcinomaOncologyDec 2027
NCT06612151YL201Phase 3Small Cell Lung CancerOncologyDec 2027
NCT07461454YL202Phase 3Locally Advanced or Metastatic Breast CancerOncologyDec 2027
NCT07258979YL201Phase 1Recurrent or Metastatic Nasopharyngeal CarcinomaOncologyFeb 2028
NCT07487896YL201Phase 3Advanced Esophageal Squamous Cell CarcinomaOncologyApr 2028
NCT06859762YL217Phase 1Advanced Solid TumorOncologyJul 2028
NCT07416994YL202Phase 3Non-Small Cell Lung CancerOncologyAug 2028
NCT07197827YL242Phase 1Advanced Solid TumorOncologySep 2028
NCT06057922YL201Phase 1Advanced Solid TumorOncologyOct 2028
NCT07407933YL201Phase 1Thoracic Neoplasms, Lung Diseases, Small Cell Lung CarcinomaOncologyNov 2028
NCT07739758YL201Phase 3SCLC, Extensive StageOncologyJun 2029
NCT06384352YL211Phase 1Advanced Solid TumorsOncologyJun 2031

Targets

B7H3 (1) PDCD1LG1 (1) PDCD1LG2 (1)

Companies with the same targets

BioNTech SE Chia Tai Tianqing Pharmaceutical Group Pfizer Hansoh BioMedical R&D Company Daiichi Sankyo Qilu Pharmaceutical IDEAYA Biosciences CSPC Megalith Biopharmaceutical Phrontline Biopharma Aktis Oncology

Companies built like this

LaNova Medicines Servier Bio-Innovation Chipscreen Biosciences CSPC Megalith Biopharmaceutical IDEAYA Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.